AJANTPHARM:NSE:NSE-Ajanta Pharma Limited (INR)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 3324.75

Change

-26.20 (-0.78)%

Market Cap

USD 418.19B

Volume

0.22M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Ajanta Pharma Limited, a specialty pharmaceutical formulation company, together with its subsidiaries, develops, manufactures, and markets speciality pharmaceutical finished dosages. The company markets and serves various therapeutic segments, such as cardiology, antidiabetic, ophthalmology, dermatology, pain management, and respiratory areas. It also provides tablets, capsules, injectables, inhalers, ointments, creams, and liquids. The company serves in India, Africa, rest of Asia, the United States, and internationally. Ajanta Pharma Limited was founded in 1973 and is headquartered in Mumbai, India. Address: Ajanta House, Mumbai, India, 400067

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-04 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
SUNPHARMA:NSE Sun Pharmaceutical Industries ..

-0.80 (-0.04%)

USD 4,554.89B
DIVISLAB:NSE Divi's Laboratories Limited

-4.75 (-0.09%)

USD 1,441.57B
TORNTPHARM:NSE Torrent Pharmaceuticals Limite..

+81.40 (+2.40%)

USD 1,154.88B
DRREDDY:NSE Dr. Reddy's Laboratories Limit..

-102.40 (-1.52%)

USD 1,121.95B
ZYDUSLIFE:NSE Zydus Lifesciences Limited

-11.70 (-1.09%)

USD 1,071.49B
MANKIND:NSE Mankind Pharma Ltd

+73.85 (+2.91%)

USD 1,033.59B
LUPIN:NSE Lupin Limited

+14.65 (+0.67%)

USD 998.11B
AUROPHARMA:NSE Aurobindo Pharma Limited

+7.45 (+0.51%)

USD 851.48B
ALKEM:NSE Alkem Laboratories Limited

+34.85 (+0.57%)

USD 740.60B
GLENMARK:NSE Glenmark Pharmaceuticals Limit..

+18.35 (+1.12%)

USD 473.60B

ETFs Containing AJANTPHARM:NSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 53.95% 73% C 79% B-
Dividend Return 1.20% 90% A- 76% C+
Total Return 55.15% 73% C 79% B-
Trailing 12 Months  
Capital Gain 90.26% 77% C+ 82% B
Dividend Return 1.49% 93% A 75% C
Total Return 91.75% 78% C+ 82% B
Trailing 5 Years  
Capital Gain 400.67% 75% C 67% D+
Dividend Return 10.44% 81% B- 63% D
Total Return 411.11% 75% C 67% D+
Average Annual (5 Year Horizon)  
Capital Gain 30.09% N/A N/A 43% F
Dividend Return 31.14% N/A N/A 43% F
Total Return 1.05% N/A N/A 65% D
Risk Return Profile  
Volatility (Standard Deviation) 33.91% N/A N/A 72% C
Risk Adjusted Return 91.85% N/A N/A 76% C+
Market Capitalization 418.19B 87% B+ 89% A-

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.